Pyridine derivatives: structure-activity relationships causing parkinsonism-like symptoms

• Published in: Reviews of environmental contamination and toxicology Vol. 122; p. 1
• Main Authors: Bachurin, S O, Tkachenko, S E, Lermontova, N N
• Format: Journal Article
• Language: English
• Published: United States 1991
• Subjects: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - adverse effects; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - chemistry; Animals; Humans; MPTP Poisoning; Parkinson Disease, Secondary - chemically induced; Pyridines - adverse effects; Pyridines - chemistry; Pyridines - toxicity; Structure-Activity Relationship
• ISSN: 0179-5953
• DOI: 10.1007/978-1-4612-3198-1_1

In recent years, sufficient evidence has surfaced to implicate low-molecular-weight organic compounds in certain known neurological disorders. At this time, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is considered the compound capable of inducing conditions most similar to idiopathic parkinsonism in clinical, biochemical, and histopathological characteristics. Substances containing MPTP-like fragments are used as herbicides, drugs and intermediates in the synthesis of many heterocyclic compounds. The mechanistic study of toxic MPTP action has enabled development of criteria for appraising potential parkinsonogenic properties of similar chemical structures. Key features of MPTP action include the following: 1. Ability to pass through the blood-brain barrier (BBB). 2. Enzymatic biotransformation to the neuroactive form (pyridine metabolites). 3. Transfer to neurons via a neuromediator reuptake system. 4. Action on intracellular targets. This review discusses data concerning the effects of metabolite structure on the major steps in the neurotropic action mechanism of MPTP-like compounds. Special attention is focused on the key steps defining the selectivity of MPTP's neuronal action, i.e., the activation step caused by monoamine oxidase (MAO) and interaction with the dopamine (DA) reuptake system. Most structural MPTP analogs (including certain pesticide preparations) used in our experiments and described in the literature exhibit no degenerative MPTP-like properties. This is probably related to the fact that each consecutive stage in the MPTP neurotoxicity mechanism makes rather stringent demands on metabolite structure. The number of structures which concurrently meet the requirements of all the processes is finite. This, however, does not invalidate the hypotheses concerning the ecotoxic nature of idiopathic parkinsonism. Possible ecotoxins may have only a partial, presymptomatic effect which, however, promotes age-related neurodegenerative processes and accelerates development of parkinsonism. This concept necessitates designing special tests of the possible neurotoxic properties of compounds found in the environment which may be functional MPTP analogs.